Zola-cel is named as an intervention in 5 current clinical trials in our USA and UK registers. None are recruiting at the moment. The most common phase is Phase 2. The lead sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The most-studied condition is Systemic Sclerosis.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 5 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 0 |
| Clinical trials in UK | 4 | 0 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our USA and UK registers name Zola-cel (also registered as BMS-986353) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 5 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zola-cel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zola-cel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zola-cel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.